MedTrace Logo

T2 FSL2 Weight Loss

NCT05168306 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2025-01-30

No results posted yet for this study

Summary

To compare the impact of the FreeStyle Libre (FSL) 2 Flash Glucose Monitoring System to the current Diabetes Monitoring standard of care (SOC) on weight reduction in subjects with type 2 diabetes.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DEVICE

FreeStyle Libre 2 Flash Glucose Monitoring System

The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older.

Sponsors & Collaborators

  • Abbott Diabetes Care

    lead INDUSTRY

Principal Investigators

  • Shridhara A Karinka, PhD · Abbott Diabetes Care

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-05
Primary Completion
2023-01-30
Completion
2023-07-19
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05168306 on ClinicalTrials.gov